13F-HR filed by Octagon Capital Advisors LP
Octagon Capital Advisors LP filed this 13F-HR for the quarter ended 2025-06-30, filed 2025-08-14, with 30 holding rows worth $455,625,029.
- Accession
- 0001839435-25-000007
- Filer
- CIK 1839435
- Filed
- 2025-08-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2025
A holdings report, 30 entries on the cover page, a total value of $455,625,029 stated on the cover page (in dollars after the unit check, H1), rows summing to $455,625,029 with VALUE read as dollars as filed, 13F file number 028-20958. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| DIANTHUS THERAPEUTICS INC | 252828108 | COM | 2,341,667 | $43,625,256 | dollars as filed | |
| ARRIVENT BIOPHARMA INC | 04272N102 | COM | 1,946,054 | $42,365,596 | dollars as filed | |
| VERONA PHARMA PLC | 925050106 | SPONSORED ADS | 337,000 | $31,873,460 | dollars as filed | |
| TAYSHA GENE THERAPIES INC | 877619106 | COMMON STOCK | 12,592,500 | $29,088,675 | dollars as filed | |
| ARS PHARMACEUTICALS INC | 82835W108 | COM | 1,350,000 | $23,557,500 | dollars as filed | |
| GOSSAMER BIO INC COM | 38341P102 | Stock | 18,350,000 | $22,570,500 | dollars as filed | |
| OCULAR THERAPEUTIX INC | 67576A100 | COM | 2,425,000 | $22,504,000 | dollars as filed | |
| MERUS N V | N5749R100 | COM | 389,000 | $20,461,400 | dollars as filed | |
| TREVI THERAPEUTICS INC COM | 89532M101 | Stock | 3,672,000 | $20,085,840 | dollars as filed | |
| COGENT BIOSCIENCES INC | 19240Q201 | COM | 2,763,000 | $19,838,340 | dollars as filed | |
| ATYR PHARMA INC | 002120202 | COM NEW | 3,820,000 | $19,367,400 | dollars as filed | |
| APELLIS PHARMACEUTICALS INC | 03753U106 | COM | 903,500 | $15,639,585 | dollars as filed | |
| NUVATION BIO INC COM CL A | 67080N101 | Stock | 7,691,334 | $14,998,101 | dollars as filed | |
| Tourmaline Bio Inc | 89157D105 | Common Stock | 905,000 | $14,470,950 | dollars as filed | |
| KALVISTA PHARMACEUTICALS INC | 483497103 | COM | 1,273,333 | $14,395,030 | dollars as filed | |
| MIND MEDICINE MINDMED INC | 60255C885 | COM NEW | 2,130,000 | $13,823,700 | dollars as filed | |
| CENTESSA PHARMACEUTICALS PLC | 152309100 | SPONSORED ADS | 1,030,000 | $13,534,200 | dollars as filed | |
| PHARVARIS NV | N69605108 | COMMON STOCK | 672,595 | $11,837,672 | dollars as filed | |
| KYMERA THERAPEUTICS INC | 501575104 | COM | 266,000 | $11,608,240 | dollars as filed | |
| ABIVAX SA- | 00370M103 | SPONSORED ADS | 1,267,000 | $9,692,550 | dollars as filed | |
| DBV TECHNOLOGIES S A | 23306J309 | SPONSORED ADS | 1,018,021 | $9,314,892 | dollars as filed | |
| CORBUS PHARMACEUTICALS | 21833P301 | COM NEW | 1,115,000 | $7,693,500 | dollars as filed | |
| MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD | 61559X104 | Stock | 148,000 | $6,985,600 | dollars as filed | |
| UNICYCIVE THERAPEUTICS INC | 90466Y202 | COMMON STOCK | 1,000,000 | $4,770,000 | dollars as filed | |
| NEUROGENE INC | 64135M105 | COMMON STOCK | 303,000 | $4,529,850 | dollars as filed | |
| HELIX ACQUISITION CORP II | G4444H101 | CL A ORD SHS | 250,000 | $2,662,500 | dollars as filed | |
| MAZE THERAPEUTICS INC COM | 578784100 | Stock | 177,667 | $2,179,974 | dollars as filed | |
| KALARIS THERAPEUTICS INC | 482929106 | COM | 360,000 | $961,200 | dollars as filed | |
| ERASCA INC COM | 29479A108 | Stock | 700,000 | $889,000 | dollars as filed | |
| NUVATION BIO INC | 67080N119 | WARR | 154,112 | $300,518 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001839435-25-000007 | this filing | 2025-08-14 | acceptance time not in the bulk data set |